Results 91 to 100 of about 40,685 (224)

Efficacy and safety of switching to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus and dyslipidaemia: A multicentre, prospective study (EROICA study)

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 906-913, February 2026.
Abstract Aims To evaluate the lipid‐lowering efficacy, safety, and adherence of switching from moderate‐ or low‐intensity statin monotherapy to ezetimibe 10 mg/rosuvastatin 2.5 mg in Korean patients with type 2 diabetes mellitus (T2DM) and dyslipidaemia.
Sangmo Hong, Won J. Kim, Sungrae Kim, Jung H. Park, Eun S. Kang, Min K. Moon, Jae T. Kim, Ji‐Oh Mok, Ki Y. Lee, Cheol‐Young Park, Chang B. Lee   +10 more
wiley   +1 more source

Neuronal PCSK9 regulates cognitive performances via the modulation of ApoER2 synaptic localization

Pharmacological Research
PCSK9 promotes the degradation of the low-density lipoprotein receptors and its inhibition by monoclonal antibodies or gene silencing approaches results in the reduction of plasma cholesterol levels coupled to that of cardiovascular events.
Silvia Pelucchi, Lorenzo Da Dalt, Giulia De Cesare, Ramona Stringhi, Laura D’Andrea, Filippo La Greca, Clara Cambria, Lina Vandermeulen, Elisa Zianni, Stefano Musardo, Silvia Roda, Fabrizia Bonacina, Sofia Nasini, Maria Giovanna Lupo, Nicola Ferri, Stefano Comai, Fabrizio Gardoni, Flavia Antonucci, Diego Scheggia, Monica Di Luca, Giuseppe Danilo Norata, Elena Marcello   +21 more
doaj   +1 more source

Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD

Liver International, Volume 46, Issue 2, February 2026.
ABSTRACT Background and Aims Dyslipidemia is common in patients with MASLD, but the frequency and significance of inherited disorders of dyslipidemia are unclear. We investigated the prevalence and significance of pathogenic variants associated with selected monogenic disorders of dyslipidemia in 3358 patients with well‐characterised MASLD. Approach We
Tae‐Hwi Schwantes‐An, Marco A. Abreu, Brent A. Neuschwander‐Tetri, Jian Wang, Xiuqing Guo, Jingyi Tan, Robert A. Hegele, Nicholas O. Davidson, Luca Lotta, Niek Verweij, Katherine P. Yates, Jerome I. Rotter, Naga Chalasani   +12 more
wiley   +1 more source

Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations

Frontiers in Pharmacology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily secreted by hepatocytes. PCSK9 is critical in liver low-density lipoprotein receptors (LDLRs) metabolism.
Fengyuan Lu, En Li, Xiaoyu Yang, Xiaoyu Yang   +3 more
doaj   +1 more source

The PCSK9 decade

Journal of Lipid Research, 2012
PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL cholesterol (LDL-C) metabolism by virtue of its pivotal role in the degradation of the LDL receptor.
Gilles Lambert, Barbara Sjouke, Benjamin Choque, John J.P. Kastelein, G. Kees Hovingh   +4 more
doaj   +1 more source

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society [PDF]

, 2014
AIMS: Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular ...
Averna, M, AVERNA, Maurizio, Boileau, C, Boileau, C, Boren, J, Boren, J, Bruckert, E, Bruckert, E, Catapano, A, Catapano, A, Chapman, M, Chapman, M, Chapman, M, Cuchel, M, Cuchel, M, Defesche, J, Defesche, J, Descamps, O, Descamps, O, Ginsberg, H, Ginsberg, H, Ginsberg, H, Hegele, R, Hegele, R, Hovingh, G, Hovingh, G, Humphries, S, Humphries, S, Kovanen, P, Kovanen, P, Kuivenhoven, J, Kuivenhoven, J, Masana, L, Masana, L, Nordestgaard, B, Nordestgaard, B, Pajukanta, P, Pajukanta, P, Parhofer, K, Parhofer, K, Raal, F, Raal, F, Ray, K, Ray, K, Santos, R, Santos, R, Stalenhoef, A, Stalenhoef, A, Steinhagen Thiessen, E, Steinhagen Thiessen, E, Stroes, E, Stroes, E, Taskinen, M, Taskinen, M, Tybjaerg Hansen, A, Tybjaerg Hansen, A, Watts, G, Watts, G, Wiegman, A, Wiegman, A, Wiklund, O, Wiklund, O.   +61 more
core   +1 more source

Anti-PCSK9 Vaccines - An Emerging Therapeutic Innovative Game Changer in Dyslipidemia and Beyond [PDF]

, 2020
Mrinal Kanti Das, Tapan Sinha, M. Chaudhary   +2 more
openalex   +1 more source

The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption

Journal of Lipid Research, 2019
Very few studies have investigated the interrelations between proprotein convertase subtilisin/kexin type 9 (PCSK9) metabolism, cholesterol synthesis, and cholesterol absorption.
Günther Silbernagel, Lars K. Steiner, Tim Hollstein, Günter Fauler, Hubert Scharnagl, Tatjana Stojakovic, Friederike Schumann, Bediha Bölükbasi, Winfried März, Elisabeth Steinhagen-Thiessen, Ulrich Laufs, Ursula Kassner   +11 more
doaj   +1 more source

Identifying low density lipoprotein cholesterol associated variants in the Annexin A2 (ANXA2) gene. [PDF]

, 2017
BACKGROUND AND AIMS: Annexin-A2 (AnxA2) is an endogenous inhibitor of proprotein convertase subtilisin/kexin type-9 (PCSK9). The repeat-one (R1) domain of AnxA2 binds to PCSK9, blocking its ability to promote degradation of low-density lipoprotein ...
Anastasia Z. Kalea, Anders Franco-Cereceda, Andrew Wong, Aroon Hingorani, Barbara J. Jefferis, Bernstein, Bharadwaj, Boardman-Pretty, Bresnick, Bulger, Cariou, Cartharius, Claudia Giambartolomei, Decker, Diana Kuh, Fairoozy, Gerke, Global Lipids Genetics C, Grewal, Grewal, Hedhli, J.P. Casas, Jackie Cooper, Jackie F. Price, Jon White, Kim, Ko, Kotowski, Kwon, Lang, Lasse Folkersen, Liu, Ly, Mayer, McDowell, Meena Kumari, Mika Kivimaki, Nassoury, Nikolaev, Peter Whincup, Pierce, Poirier, Rebecca Hardy, Reva, Roaa Hani Fairoozy, S. Goya Wannamethee, Seidah, Seidah, Spano, Stela McLachlan, Steve E. Humphries, Thomas Grewal, Tom R. Gaunt, Turley, Ward, Ward, Westra, Yoav Ben-Shlomo, Yusufzai, Zweig   +59 more
core   +5 more sources

Rationale and Design of the PASSIVATE‐CAP Trial: The Preventive Intervention Value of Drug‐Coated Balloons in Vulnerable Coronary Atherosclerotic Plaques

Clinical Cardiology, Volume 49, Issue 1, January 2026.
PASSIVATE‐CAP Research Overview and Flowchart. ABSTRACT Background Patients with acute coronary syndrome (ACS) face a significantly increased risk of cardiovascular events due to vulnerable plaques. However, no clear evidence supports performing preventive percutaneous coronary intervention (PCI) for non‐flow‐limiting vulnerable plaques.
Zhongxiu Chen, Junyan Zhang, Minggang Zhou, Shichu Liang, Yong Chen, Chen Li, Hua Wang, Jiafu Wei, Baotao Huang, Mian Wang, Yong He, for the PASSIVATE‐CAP trial investigator   +11 more
wiley   +1 more source